Company / Shareholders' Equity
Perspective Therapeutics, Inc. Shareholders' Equity History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$54.6M
FY2022
5-year range
$5.0M / $54.6M
FY2018-FY2022
Trend
+611.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity changed +611% YoY in FY2022, a notable deviation from the 9-year average annual change of +98%.
Based on SEC 10-K filings.
$55M in FY2022 with a 5-year CAGR of +21.3%.
Improved from $5M to $55M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +72.7%
- 5-Year CAGR
- +21.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +21.3%, indicating consistent growth.
- In FY2022, shareholders' equity increased 611.5% year-over-year.
- Lowest shareholders' equity in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $54.6M | +611.5% |
| FY2021 | $7.7M | +52.7% |
| FY2020 | $5.0M | -52.6% |
| FY2019 | $10.6M | -35.4% |
| FY2018 | $16.4M | -21.1% |
| FY2017 | $20.8M | -13.2% |
| FY2016 | $24.0M | +346.4% |
| FY2015 | $5.4M | -7.8% |
| FY2014 | $5.8M | +0.0% |
| FY2013 | $5.8M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026